Methods |
RCT
Assessor blinded
1985‐1986 |
Participants |
Number: 352 episodes
Age: mean 46, range 15‐82 |
Interventions |
ticalcillin/clavulanate 4gr/0.1grX6 + vancomycin 1grX2
versus
ceftazidime 1grX6 + vancomycin 1grX2
A third arm not included in this review assessed all 3 antibiotics combined. |
Outcomes |
Clinical and microbiological failure
Superinfection
Adverse events |
Notes |
USA |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Adequate sequence generation? |
Low risk |
Computer‐generated sequence |
Allocation concealment? |
Low risk |
No description, but previous trials in the center were conducted using the pharmacy as the center of randomization and allocation was disclosed only after patients' entered the trial |
Blinding?
All outcomes |
High risk |
Response to therapy was evaluated by an investigator who was not involved in the patient's care and who was unaware of the regimen used |
Incomplete outcome data addressed?
All‐cause mortality |
Unclear risk |
Mortality not reported in study |
Incomplete outcome data addressed?
Treatment failure |
High risk |
Number of dropouts (11%) known per study group |
Free of other bias? |
High risk |
Unit of randomization = episodes; patients to episodes ratio 0.86 |